Frequency of patients carrying gene mutations at baseline
| . | Eltrombopag (n = 101) . | Placebo (n = 110) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| MDS genes (53 genes analyzed), n (%) | ||||
| Mutation carrier | 86 (85.1) | 101 (91.8) | 0.51 (0.19-1.32) | .14 |
| Mutation noncarrier | 15 (14.9) | 9 (8.2) | ||
| Prognostic genes (18 genes analyzed), n (%) | ||||
| Mutation carrier | 77 (76.2) | 96 (87.3) | 0.47 (0.21-1.02) | .048 |
| Mutation noncarrier | 24 (23.8) | 14 (12.7) |
| . | Eltrombopag (n = 101) . | Placebo (n = 110) . | OR (95% CI) . | P . |
|---|---|---|---|---|
| MDS genes (53 genes analyzed), n (%) | ||||
| Mutation carrier | 86 (85.1) | 101 (91.8) | 0.51 (0.19-1.32) | .14 |
| Mutation noncarrier | 15 (14.9) | 9 (8.2) | ||
| Prognostic genes (18 genes analyzed), n (%) | ||||
| Mutation carrier | 77 (76.2) | 96 (87.3) | 0.47 (0.21-1.02) | .048 |
| Mutation noncarrier | 24 (23.8) | 14 (12.7) |